Otros idiomas Tonix Pharmaceuticals Holding Corp.

Acciones

TNXP

US8902608541

Mercado cerrado - Nasdaq Otros sitios de cotización 22:00:00 17/05/2024			Después de cerrar 13:52:40
0,1972 ^USD	+8,59 %		0,205	+3,96 %

01/04	Tonix Pharmaceuticals Holding Corp. informa de los resultados del cuarto trimestre finalizado el 31 de diciembre de 2023	CI
01/04	Tonix Pharmaceuticals Holding Corp. presenta los resultados del ejercicio cerrado el 31 de diciembre de 2023	CI

Otros idiomas

Desbloquee todas las noticias sobre todas las empresas: ¡No vuelvas a perderse una oportunidad de inversión rentable!

Inscripción 100% Gratuita

Tonix Pharmaceuticals to Present at the Alliance Global Partners (A.G.P) Healthcare Company Showcase	15/05
Tonix Pharmaceuticals Reports First Quarter 2024 Financial Results and Operational Highlights	13/05
Tonix Pharmaceuticals : Factsheet	30/04
Tonix Pharmaceuticals Announces Presentation at Planet MicroCap Showcase	24/04
Tonix Pharmaceuticals : Investor Presentation April 2024	19/04
Tonix Pharmaceuticals : TNX-102 SL for Fibromyalgia and Long COVID	09/04
Tonix Pharmaceuticals Holding Corp. Reports Earnings Results for the Fourth Quarter Ended December 31, 2023	01/04
Tonix Pharmaceuticals Holding Corp. Reports Earnings Results for the Full Year Ended December 31, 2023	01/04
Tonix Pharmaceuticals Reports Fourth Quarter and Full Year 2023 Financial Results and Operational Highlights	01/04
Tonix Pharmaceuticals Prices $4.4 Million Direct Offering; Revises Existing Warrant Terms -- Shares Tumble	28/03
Tonix Pharmaceuticals Announces Pricing of $4.4 Million Registered Direct Offering	28/03
Tonix Pharmaceuticals Gets Rare Pediatric Disease Label For TNX-2900 to Treat Prader-Willi Syndrome	25/03
Tonix Pharmaceuticals Receives Rare Pediatric Disease Designation from the FDA for TNX-2900 for the Treatment of Prader-Willi Syndrome	25/03
Tonix Pharmaceuticals Announces Poster Presentation Describing Discovery of Novel Next-Generation Oxytocin Analogues at the American Chemistry Society (ACS) Spring 2024 Meeting	21/03
Tonix Pharmaceuticals Announces Poster Presentation Describing Discovery of Novel Next-Generation Oxytocin Analogues At the American Chemistry Society Spring 2024 Meeting	21/03
Tonix Pharmaceuticals Announces Selection of Two Contract Manufacturing Organizations for the Launch and Commercial Manufacture of Tonmya™ for the Management of Fibromyalgia	20/03
Tonix Pharmaceuticals Announces Transition to Fully Integrated Biopharmaceutical Company Expected on April 1, 2024	19/03
Tonix Pharmaceuticals : TNX-102 SL for Fibromyalgia and Long COVID	13/03
Tonix Pharmaceuticals Announces Presentation at BIO-Europe Spring	12/03
Tonix Pharmaceuticals Reports Improvement in ?Brain Fog,? in Fibromyalgia Patients Treated with Tonmya? in Resilient, an Nda-Enabling Phase 3 Clinical Trial	11/03

No hay resultados para esta búsqueda

Todas Recomendaciones analistas Eventos destacados Insiders Transcripts Comunicados Publs. oficiales Otros idiomas Ideas de trading Artículos de MarketScreener Estrategias MarketScreener

Otros idiomas Tonix Pharmaceuticals Holding Corp.

Acciones

TNXP

US8902608541

Otros idiomas

Filtros